BACKGROUND: Toll-like receptors (TLRs) play an important role in the innate immune response to pathogens. TLR8 has been found to recognize RNA derived from various viruses, including human immunodeficiency virus (HIV). Presently, very little is known about the influence of TLR8 genetic variation on susceptibility to and progression of HIV disease. METHODS AND RESULTS: We genotyped a population of 782 HIV-positive adults and 550 healthy control subjects for 3 nonsynonymous TLR8 single-nucleotide polymorphisms. We found that the presence of the most frequent TLR8 polymorphism, TLR8 A1G (rs3764880), confers a significantly protective effect regarding progression of the disease. In overexpression assays, we demonstrated that this receptor variant displays impaired NF-kappaB activation in vitro. Furthermore, we analyzed different cell types obtained from individuals differing in their TLR8 genotype and assessed their response to TLR8 ligands in vitro. The presence of the mutated receptor variant was associated with modulation of cytokine secretion profiles and lipid mediator synthesis patterns in monocytes and neutrophils. CONCLUSIONS: This first report of a functional TLR8 variant associated with a different clinical course of an RNA viral disease may have implications for the individual risk assessment of patients infected with HIV and other RNA viruses as well as for future HIV vaccine development.
BACKGROUND: Toll-like receptors (TLRs) play an important role in the innate immune response to pathogens. TLR8 has been found to recognize RNA derived from various viruses, including human immunodeficiency virus (HIV). Presently, very little is known about the influence of TLR8 genetic variation on susceptibility to and progression of HIV disease. METHODS AND RESULTS: We genotyped a population of 782 HIV-positive adults and 550 healthy control subjects for 3 nonsynonymous TLR8 single-nucleotide polymorphisms. We found that the presence of the most frequent TLR8 polymorphism, TLR8 A1G (rs3764880), confers a significantly protective effect regarding progression of the disease. In overexpression assays, we demonstrated that this receptor variant displays impaired NF-kappaB activation in vitro. Furthermore, we analyzed different cell types obtained from individuals differing in their TLR8 genotype and assessed their response to TLR8 ligands in vitro. The presence of the mutated receptor variant was associated with modulation of cytokine secretion profiles and lipid mediator synthesis patterns in monocytes and neutrophils. CONCLUSIONS: This first report of a functional TLR8 variant associated with a different clinical course of an RNA viral disease may have implications for the individual risk assessment of patients infected with HIV and other RNA viruses as well as for future HIV vaccine development.
Authors: Romel D Mackelprang; Abigail W Bigham; Connie Celum; Guy de Bruyn; Kristin Beima-Sofie; Grace John-Stewart; Allan Ronald; Nelly R Mugo; Kati J Buckingham; Michael J Bamshad; James I Mullins; M Juliana McElrath; Jairam R Lingappa Journal: J Infect Dis Date: 2013-12-10 Impact factor: 5.226
Authors: Natalia M Astakhova; Andrey A Perelygin; Andrey A Zharkikh; Teri L Lear; Stephen J Coleman; James N MacLeod; Margo A Brinton Journal: Immunogenetics Date: 2009-07-01 Impact factor: 2.846
Authors: Holly D Clifford; Stephanie T Yerkovich; Siew-Kim Khoo; Guicheng Zhang; John Upham; Peter N Le Souëf; Peter Richmond; Catherine M Hayden Journal: Immunogenetics Date: 2011-09-23 Impact factor: 2.846
Authors: Amber M Paul; Dhiraj Acharya; Linda Le; Penghua Wang; Dobrivoje S Stokic; A Arturo Leis; Lena Alexopoulou; Terrence Town; Richard A Flavell; Erol Fikrig; Fengwei Bai Journal: J Immunol Date: 2016-10-21 Impact factor: 5.422
Authors: Nicole Lenz; Tobias Schindler; Benjamin M Kagina; Jitao David Zhang; Tedson Lukindo; Maxmillian Mpina; Peter Bang; Ingrid Kromann; Søren T Hoff; Peter Andersen; Klaus Reither; Gavin J Churchyard; Ulrich Certa; Claudia A Daubenberger Journal: Clin Vaccine Immunol Date: 2015-04-29